BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Testosterone: Phase III data

Top-line data from the double-blind, North American Phase III BLOOM-2 trial in 575 surgically menopausal women showed that transdermal LibiGel missed the co-primary endpoints of significantly increasing the total number of days with a satisfying sexual event (1 vs. 1.28 days, p=0.214) and of significantly increasing mean sexual desire from baseline to 6 months vs. placebo (p=0.48). On...

Read the full 266 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >